NCT03468218 - Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 18, 2018

Primary Completion Date

May 2, 2022

Study Completion Date

October 29, 2025

Conditions

Metastatic Head and Neck CarcinomaParanasal Sinus Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaRecurrent Oral Cavity Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaStage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7Unresectable Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

Cabozantinib

Given PO

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (2)

30308

Emory University Hospital Midtown, Atlanta

33612

Moffitt Cancer Center, Tampa